

ISLHD HAEMATOLOGY CLINICAL TRIALS

Illawarra Cancer Care Centre

March 2024

ISLHD CANCER CLINICAL TRIALS UNIT

**Illawarra Cancer Care Centre
Wollongong Hospital
Loftus Street
Wollongong NSW 2500**

Ph: 02 4253 4384

Fax: 02 4222 5085

**Email: ISLHD-
CancerClinicalTrials@health.
nsw.gov.au**

Clinical Trials available through the Illawarra Shoalhaven Local Health District can be found on the ClinTrial Refer App. Scan the QR code below to download ClinTrial Refer.



The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Multiple Myeloma
- Acute myeloid Leukaemia

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Haematology Trials Clinician, please phone Haematology on 02 4253 4009

ISLHD Haematology Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

Scan the QR Code for more information including eligibility criteria

Multiple Myeloma

CA057-001: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM).

Dr Parmar
Kiara Porter/
Danielle Di
Pietro
***Satellite site**



IRAKLIA: A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM).

Dr Parmar
Tiffany
Koutsouradis/
Jillian Dubose



IZALCO: A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM). ****Recruitment paused****

Dr Parmar
Felicity
Carroll-Cross/
Cassandra
Jory



MonumenTAL-2: A multi-arm phase 1b study of talquetamab with other anticancer therapies in participants with multiple myeloma.

Dr Parmar
Edwina Petre/
Tegan Cutter



MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Dr Parmar
Tegan Cutter/
Edwina Petre



TCD17710: First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light chain amyloidosis (RRLCA). ****Recruitment paused****

Dr Parmar
Felicity
Carroll-Cross/
Carla Brown



LTS17704: International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study.

Dr Parmar
Tiffany
Koutsouradis/
Amelia
Feneck



ISLHD Haematology Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

Scan the QR Code for more information including eligibility criteria

Acute Leukaemia

AML M22/D2: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Dr Presgrave
Carla Brown



For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email ISLHD-HaematologyTrials@health.nsw.gov.au

Trial Coordinator	Availability	Contact details
Danielle Di Pietro (team leader)	Mon-Fri	02 4255 1415
Felicity Carroll-Cross	Mon-Fri	02 4253 4039
Tegan Cutter	Mon-Fri	02 4222 5553
Kiara Porter	Mon-Fri	02 4222 5276
Carla Brown	Tues-Thurs	02 4253 4082
Cassandra Jory	Wed-Fri	02 4222 5227
Tiffany Koutsouradis	Wed-Fri	02 4253 4082
Jillian Dubose	Tues-Fri	02 4255 1495
Amelia Feneck	Mon-Wed	02 4222 5230
Edwina Petre	Mon, Wed, Thurs	02 4253 4173